Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.

Miami man pleads guilty to selling adulterated, misbranded HIV drugs across U.S.


A Miami man has pleaded guilty in federal court to distributing adulterated HIV drugs dispensed to U.S. patients.

Miami Herald | Tribune News Service | Getty Images

A Miami man pleaded guilty to distributing as much as $25 million worth of misbranded and adulterated HIV drugs that were dispensed by pharmacies across the U.S. to unsuspecting patients, federal prosecutors said.

Armando Herrera, 43, faces a maximum possible sentence of five years in prison for the crime.

Herrera pleaded guilty in U.S. District Court in Miami on Monday to one count of conspiracy to introduce adulterated and misbranded drugs in the U.S. market, court filings show.

A medication is adulterated if a substance has been substituted for the drug in whole or in part.

Herrera and his co-conspirators set up companies in Texas, California and Washington state that acquired large quantities of misbranded and adulterated HIV medication from legal channels, falsified the pills’ packaging and sold them at a steep discount to wholesalers that later sold them to pharmacies, court documents say.

Prosecutors said the wholesalers were involved in the criminal scheme, but the pharmacies were unaware that the drugs were altered or misbranded.

The adulterated and misbranded drugs included Truvada, Biktarvy and other unnamed medications.

Truvada is prescribed to prevent HIV infection in people who are at risk of contracting the virus. The medication is also used in combination with other drugs to treat infection.

Biktarvy is prescribed to treat HIV infection. Truvada and Biktarvy are manufactured by Gilead Sciences.

Herrera and his co-conspirators received between $16.7 million and $25 million in payment from two wholesalers, according to court filings.

The filings did not say how Herrera and his co-conspirators acquired the drugs.

Medications are often siphoned off the legal market by purchasing them from individual patients who were prescribed the drugs.

Herrera is scheduled to be sentenced Dec. 21. His lawyer did not immediately respond to CNBC’s request for comment.



Source

CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More